FDA Issues Final Potency Assurance Guidance for Cell and Gene Therapy Manufacturers

Batch release testing, raw material controls, and post-approval monitoring for cellular and gene therapy products now operate under a revised regulatory framework: FDA's final Potency Assurance for Cellular and Gene Therapy Products guidance, published November 2, 2026, replaces the agency's 2011 potency testing guidance and establishes a science- and risk-based strategy that applies from IND submission through BLA approval and post-market verification.

The updated framework requires manufacturers to demonstrate, before any batch reaches a patient, that potency meets a defined therapeutic standard. That obligation extends across the full product lifecycle. For QA directors and manufacturing heads, the practical shift is in scope: the guidance integrates potency considerations at every development and commercialization stage, not solely at the point of batch release. Controls for raw material variability, in-process testing, and biological activity confirmation are each addressed within the strategy.

The guidance also introduces tailored recommendations for product categories that present distinct manufacturing challenges. Viral vector gene therapies, products with short shelf lives, and patient-specific autologous therapies each carry considerations that standard potency frameworks have not historically resolved with precision. Manufacturers working in these segments should expect to map existing quality systems against the new recommendations and identify gaps before regulatory interactions advance.

For facilities already operating under 21 CFR Part 211 or biologics-specific GMP requirements, the guidance does not introduce new statutory obligations but does clarify how FDA expects manufacturers to satisfy existing ones. The risk-based structure allows flexibility in assay selection and testing strategy, provided the scientific rationale is documented and defensible. That flexibility, however, places the evidentiary burden squarely on the manufacturer to justify any deviation from conventional potency testing approaches.

Karim Mikhail, Director of the Center for Biologics Evaluation and Research, framed the guidance as aligning product quality standards with the complexity of the patient population these therapies serve, noting that recipients are frequently managing cancers or rare diseases with limited alternative treatment options.

FDA will host an implementation webinar on December 10, 2026, offering manufacturers a structured opportunity to clarify interpretation questions before those questions surface during inspections or application reviews. QA and regulatory affairs teams with active IND or BLA submissions in the CGT space should treat that date as a checkpoint for internal alignment on potency strategy documentation.

The degree to which manufacturers can demonstrate a coherent, lifecycle-spanning Potency Assurance Strategy in their next regulatory submission will likely become a visible differentiator in FDA review timelines for CGT programs.

Source: U.S. Food and Drug Administration via FDA Press Releases RSS Feed, November 2, 2026. Implementation webinar scheduled December 10, 2026.